Switching to once-daily evidence-based [beta]-blockers in patients with systolic heart failure or left ventricular dysfunction after myocardial infarction.
Albert
Nancy M
NM
Division of Nursing, Cleveland Clinic Foundation, Cleveland, Ohio, USA. albertn@ccf.org
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D000465:Algorithms; D002227:Carbazoles / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000077261:Carvedilol; D003692:Delayed-Action Preparations; D019317:Evidence-Based Medicine; D054143:Heart Failure, Systolic / Q000188:drug therapy* / Q000209:etiology / Q000451:nursing; D006801:Humans; D008790:Metoprolol / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000150:complications* / Q000534:rehabilitation; D010349:Patient Compliance; D019338:Polypharmacy; D011412:Propanolamines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D013810:Therapeutic Equivalency; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy* / Q000209:etiology / Q000451:nursing
D000319:Adrenergic beta-Antagonists; D002227:Carbazoles; D003692:Delayed-Action Preparations; D011412:Propanolamines; D000077261:Carvedilol; D008790:Metoprolol